Search PubMed⌕ Search

Biomedical subjects

A Piana

Publications and source records attributed to A Piana.

At least 55 records · Page 3Linked to original sources
PubMed1981

[Platelet function in the dog].

Platelet aggregation with Born test was performed in 9 normal dogs. ADP, Epinephrine and Collagen were employed to stimulate platelets. With ADP, canine platelet aggregation was lower than human platelet aggregation, while, with Epinephrine and Collagen, aggregation was similar to that obtained with human platelets. Therefore the dog might be a model to study pharmacological interactions on platelet function.

Adenosine Diphosphate↗
PubMed1979

[Changes induced with varying solutions of normal plasma on granulocyte capillary tube migration].

In the present work we have evaluated the effect of decreasing concentrations of normal plasma in TC 199 on leukocyte capillary migration. From the 1st to the 4th hour of migration, normal plasma at 100%-80%-60%-40% concentration, significantly inhibits leukocyte migration. The inhibitory effect is lost, only by a few plasmas, at 60% and 40% concentration, during the following migration hours. Normal plasma at 20% and 10% concentration doesn't show any inhibitory effect on leukocyte capillary migration. Therefore, for clinical studies on pathological plasmas we recommend the use o plasma at 20% or 10% concentration to avoid aspecific inhibition.

Cell Movement↗
PubMed1979

[Standardization of the method of granulocyte capillary tube migration].

In the present work a method is described to standardize each step of leukocyte capillary tube migration assay. The conclusions of our study are: natrium heparin can be used as anticoagulant; the use of calibrated microcapillaries is recommended; migration chambers must lay on a horizontal surface; results can be evaluated by a ocular for radial immunodiffusion from the 16th to 20th hour of migration.

Cell Movement↗
PubMed1977

[Evaluation of the cell-mediated immune response after administration of Salmonella antigens in patients with multiple myeloma].

Myeloma patients show an impairment of several immunological functions leading to infectious diseases. In this study we evaluated cell-mediated responsiveness in a group of these patients. Six myeloma patients received full doses of I.S.M. Enterovaccino. LIF production by peripheral blood lymphocytes against Salmonella antigens was evaluated after 14 days. All patients studied showed no LIF production.

Adult↗
PubMedDate not supplied

Negative interaction of aspirin and streptokinase in acute ischemic stroke: further analysis of the Multicenter Acute Stroke Trial-Italy.

BACKGROUND: Thrombolytic therapy improves the functional outcome in acute ischemic stroke, but the risk of death and cerebral hemorrhage remains high. Aspirin given together with a thrombolytic agent may worsen the risk-to-benefit ratio. We performed a further Multicenter Acute Stroke Trial-Italy (MAST-I) which is the only randomized, controlled trial that has tested the effect of this combination to evaluate the risk of aspirin use plus streptokinase. PATIENTS AND METHODS: We made a post hoc analysis of the MAST-I results comparing streptokinase plus aspirin (156 patients) with streptokinase alone (157 patients). We evaluated the risk of death and cerebral hemorrhage. RESULTS: The combined regimen significantly increased early case fatality from day 3-10 (53 vs. 30; OR 2.1; CI 1.2-3.6). The death excess was solely due to treatments and was not explained by the main prognostic predictors (multifactorial analysis). The cause of death in the combination group was mainly cerebral (42 vs. 24; OR 2.0; CI 1.3-3.7) and associated with hemorrhagic transformation (22 vs. 11; OR 2.2; CI 1.0-5.0). The rate of stroke reoccurrence was not increased in patients treated with streptokinase alone (15 vs. 11; OR 1.4; CI 0.6-3.4). CONCLUSIONS: Stroke patients treated with streptokinase plus aspirin have an increased risk of early death, probably due to cerebral hemorrhagic complications. Whenever thrombolytics are chosen for acute stroke treatment, aspirin and other antiplatelet agents should be avoided.

Acute Disease↗